Sulfonylurea News and Research

RSS
FDA approves ONGLYZA to treat type 2 diabetes patients with renal impairment

FDA approves ONGLYZA to treat type 2 diabetes patients with renal impairment

Health Canada approves Eli Lilly's BYETTA for treatment of adults with type 2 diabetes

Health Canada approves Eli Lilly's BYETTA for treatment of adults with type 2 diabetes

FDA accepts Merck's JANUMET extended-release formulation NDA for type 2 diabetes

FDA accepts Merck's JANUMET extended-release formulation NDA for type 2 diabetes

GLUMETZA tablets are now available to wholesalers and physicians

GLUMETZA tablets are now available to wholesalers and physicians

Amylin, Lilly submit BYETTA sNDA for type 2 diabetes

Amylin, Lilly submit BYETTA sNDA for type 2 diabetes

Takeda completes settlements in patent litigation over generic ACTOS, ACTOplus met, and duetact ANDAs

Takeda completes settlements in patent litigation over generic ACTOS, ACTOplus met, and duetact ANDAs

FDA issues complete response letter for BYDUREON NDA

FDA issues complete response letter for BYDUREON NDA

En Ze Jia Shi Pharmaceuticals receives patent for controlled-release oral gliclazide

En Ze Jia Shi Pharmaceuticals receives patent for controlled-release oral gliclazide

Australian reimbursement committee is set to consider Novo Nordisk's type 2 diabetes treatment

Australian reimbursement committee is set to consider Novo Nordisk's type 2 diabetes treatment

sanofi-aventis announces top-line results from lixisenatide Phase III GETGOAL-L-ASIA trial for Type-2 Diabetes

sanofi-aventis announces top-line results from lixisenatide Phase III GETGOAL-L-ASIA trial for Type-2 Diabetes

Takeda underscores commitment to ACTOS following FDA and EMA announcements for rosiglitazone

Takeda underscores commitment to ACTOS following FDA and EMA announcements for rosiglitazone

Boehringer Ingelheim to present linagliptin Phase III data at 46th EASD

Boehringer Ingelheim to present linagliptin Phase III data at 46th EASD

Sanofi-aventis releases Lantus(R) study results for type 2 diabetes

Sanofi-aventis releases Lantus(R) study results for type 2 diabetes

ACTOS offers safety profile regarding risk of CV events in people with type 2 diabetes: Takeda

ACTOS offers safety profile regarding risk of CV events in people with type 2 diabetes: Takeda

Study: ONGLYZA and metformin improve HbA1c levels for adult patients with type 2 diabetes at 76-weeks

Study: ONGLYZA and metformin improve HbA1c levels for adult patients with type 2 diabetes at 76-weeks

Amylin presents improved indices of beta-cell function after three years of BYETTA(R) therapy

Amylin presents improved indices of beta-cell function after three years of BYETTA(R) therapy

First placebo-controlled clinical study results of BYETTA injection with Lantus presented at ADA 2010

First placebo-controlled clinical study results of BYETTA injection with Lantus presented at ADA 2010

Linagliptin mono- and combination therapy improves blood glucose control

Linagliptin mono- and combination therapy improves blood glucose control

Roche reports results of 5 taspoglutide Phase III studies for type 2 diabetes at 70th ADA

Roche reports results of 5 taspoglutide Phase III studies for type 2 diabetes at 70th ADA

JANUMET results in greater blood sugar reductions in patients with type 2 diabetes compared to pioglitazone

JANUMET results in greater blood sugar reductions in patients with type 2 diabetes compared to pioglitazone